AffyImmune, a clinical-stage biotechnology company committed to developing novel, first-in-class CAR T cell therapies, announced the appointment of Daniel Janse, Ph.D. as President and...
Kyverna Therapeutics, Inc, a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announces today the publication in...
On the July 12, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and ACT Therapeutics (Seogkyoung-Kong, CEO), developing next-generation chimeric antigen receptor...
